Skip to main content
. 2013 Oct 17;105(22):1677–1683. doi: 10.1093/jnci/djt282

Figure 2.

Figure 2.

Examples of quantitative interaction: pazopanib vs placebo for locally advanced or metastatic renal cell carcinoma patients with high interleukin 6 (IL-6) values (A) and low IL-6 values (B) [adapted from Figure 2 of Tran et al. (14). Reprinted with permission. Copyright 2012 Elsevier]. Erlotinib maintenance therapy vs placebo for non–small cell lung cancer patients with EGFR mutation–positive tumors (C) and EGFR wild-type tumors (D) [adapted from Figure 3 of Brugger et al. (15). Reprinted with permission. Copyright 2011 American Society of Clinical Oncology]. Note that data were not available from Brugger et al. (15) to provide the number of patients at risk for (C) and (D). CI = confidence interval; HR = hazard ratio; PFS = progression-free survival.